Balchem Corporation to Attend CJS Securities Virtual Conference with CEO and CFO on January 14, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 02 2026
0mins
Should l Buy BCPC?
Source: Globenewswire
- Executive Attendance: Balchem Corporation will participate in the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026, featuring CEO Ted Harris, CFO Martin Bengtsson, and Senior Director of Investor Relations Allison Baurichter, showcasing the company's leadership in health and nutrition markets.
- Business Diversification: Balchem operates through three segments—Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products—providing customized food and beverage ingredient systems that cater to diverse needs across the food, supplement, and pharmaceutical industries, enhancing its competitive edge.
- Industry Influence: The company focuses on developing and manufacturing specialty ingredients that improve global health and well-being, offering high-quality solutions that further solidify its influence in the global health and nutrition market.
- Future Outlook: By participating in industry conferences, Balchem not only demonstrates its innovative capabilities but also lays the groundwork for future market expansion and business growth, aiming to seize ongoing growth opportunities in the health and nutrition sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCPC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCPC
About BCPC
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. Its segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). The ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. The Specialty Products segment re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Balchem Corporation Q1 Earnings Announcement Scheduled
- Earnings Release Date: Balchem Corporation is set to announce its Q1 earnings on April 30th before market open, with a consensus EPS estimate of $1.33, reflecting a 9.0% year-over-year growth, indicating sustained profitability.
- Revenue Expectations: The expected revenue for Q1 is $266.5 million, representing a 6.4% year-over-year increase, showcasing Balchem's robust market performance and rising product demand.
- Performance Beat Record: Over the past two years, Balchem has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating consistency in financial performance and strong market confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward revisions, while revenue estimates have experienced two upward revisions and one downward revision, reflecting analysts' optimistic outlook on Balchem's future performance.
See More
Balchem Corporation: Stability and Investment Value in Formulation-Embedded Economics
- Consistent Profitability: Balchem has achieved profitability every year for over fifty years, with 2025 revenue surpassing $1.037 billion for the first time, demonstrating its strong competitive position and stable financial performance in the market.
- Dividend Growth Record: The company has increased its dividend for 17 consecutive years, with a 10.3% increase in 2025, reflecting management's confidence in future profitability while providing reliable cash flow for investors.
- Market Positioning Advantage: Balchem's microencapsulation technology has established strong customer relationships in the food and pharmaceutical industries, where the cost of switching suppliers can take months of reformulation and testing, ensuring a recurring revenue stream for the company.
- Regulatory Protection Effect: The EU's anti-dumping duties on Chinese choline chloride provide structural protection for Balchem's animal nutrition business, expected to last for five years, enhancing its competitiveness in the European market.
See More
Harvey Partners Acquires New Position in Balchem Corporation
- New Investment Disclosure: Harvey Partners disclosed a new position in Balchem Corporation by acquiring 116,000 shares worth $17.79 million in Q4 2026, indicating confidence in the company's growth potential.
- Holding Proportion Analysis: This acquisition positions Balchem to represent 1.6% of Harvey Partners' reportable AUM of $1.13 billion, highlighting its significance within the fund's portfolio.
- Strong Financial Performance: Balchem achieved record net sales of $1 billion in 2025, an 8.8% increase year-over-year, with net income rising to $154.85 million, up 20.5%, showcasing robust performance in the nutrition and health sectors.
- Solid Financial Position: With a cash balance of $74.6 million and a net debt leverage of only 0.3 times adjusted EBITDA, Balchem's management repurchased $107.6 million in stock in 2025, further boosting investor confidence.
See More
Balchem Corporation Reports Record Q4 2025 Earnings and Growth
- Record Sales Performance: Balchem achieved consolidated revenues of $264 million in Q4 2025, reflecting a 9.8% year-over-year increase, with Human Nutrition & Health sales reaching $166 million, marking the company's first-ever annual sales exceeding $1 billion, indicating strong market demand and growth potential.
- Enhanced Profitability: The company reported adjusted EBITDA of $68 million for Q4, with a gross margin of 25.8% and net income of $39 million, demonstrating significant improvements in cost control and operational efficiency, further solidifying its market position.
- International Market Expansion: In 2025, over half of Balchem's sales growth originated from markets outside the United States, highlighting the success of its globalization strategy, which is expected to provide robust momentum for continued growth in the future.
- Ongoing Investments and Buybacks: The company invested $43 million in capital projects and repurchased approximately 685,000 shares at an average cost of $158 per share, while also increasing its annual dividend to $0.96, marking the 17th consecutive year of dividend growth, reflecting confidence in its financial health and commitment to shareholders.
See More
Balchem (BCPC) Q4 2025 Earnings Call Transcript
See More
Balchem Q4 Earnings Exceed Expectations
- Earnings Beat: Balchem reported a Q4 Non-GAAP EPS of $1.31, exceeding expectations by $0.03, which underscores the company's robust profitability and enhances investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $263.6 million, reflecting a 9.8% year-over-year increase and surpassing expectations by $4.01 million, indicating strong sales performance across all business segments.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $67.9 million, showcasing the company's success in cost management and operational efficiency, thereby strengthening its competitive position in the market.
- Strong Free Cash Flow: With free cash flow of $51.2 million and cash flows from operations at $67.3 million, Balchem demonstrates solid cash generation capabilities, providing strong support for future investments and shareholder returns.
See More
Balchem Corporation Q1 Earnings Announcement Scheduled
- Earnings Release Date: Balchem Corporation is set to announce its Q1 earnings on April 30th before market open, with a consensus EPS estimate of $1.33, reflecting a 9.0% year-over-year growth, indicating sustained profitability.
- Revenue Expectations: The expected revenue for Q1 is $266.5 million, representing a 6.4% year-over-year increase, showcasing Balchem's robust market performance and rising product demand.
- Performance Beat Record: Over the past two years, Balchem has beaten EPS estimates 100% of the time and revenue estimates 75% of the time, demonstrating consistency in financial performance and strong market confidence.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward revisions, while revenue estimates have experienced two upward revisions and one downward revision, reflecting analysts' optimistic outlook on Balchem's future performance.
See More
Balchem Corporation: Stability and Investment Value in Formulation-Embedded Economics
- Consistent Profitability: Balchem has achieved profitability every year for over fifty years, with 2025 revenue surpassing $1.037 billion for the first time, demonstrating its strong competitive position and stable financial performance in the market.
- Dividend Growth Record: The company has increased its dividend for 17 consecutive years, with a 10.3% increase in 2025, reflecting management's confidence in future profitability while providing reliable cash flow for investors.
- Market Positioning Advantage: Balchem's microencapsulation technology has established strong customer relationships in the food and pharmaceutical industries, where the cost of switching suppliers can take months of reformulation and testing, ensuring a recurring revenue stream for the company.
- Regulatory Protection Effect: The EU's anti-dumping duties on Chinese choline chloride provide structural protection for Balchem's animal nutrition business, expected to last for five years, enhancing its competitiveness in the European market.
See More
Harvey Partners Acquires New Position in Balchem Corporation
- New Investment Disclosure: Harvey Partners disclosed a new position in Balchem Corporation by acquiring 116,000 shares worth $17.79 million in Q4 2026, indicating confidence in the company's growth potential.
- Holding Proportion Analysis: This acquisition positions Balchem to represent 1.6% of Harvey Partners' reportable AUM of $1.13 billion, highlighting its significance within the fund's portfolio.
- Strong Financial Performance: Balchem achieved record net sales of $1 billion in 2025, an 8.8% increase year-over-year, with net income rising to $154.85 million, up 20.5%, showcasing robust performance in the nutrition and health sectors.
- Solid Financial Position: With a cash balance of $74.6 million and a net debt leverage of only 0.3 times adjusted EBITDA, Balchem's management repurchased $107.6 million in stock in 2025, further boosting investor confidence.
See More
Balchem Corporation Reports Record Q4 2025 Earnings and Growth
- Record Sales Performance: Balchem achieved consolidated revenues of $264 million in Q4 2025, reflecting a 9.8% year-over-year increase, with Human Nutrition & Health sales reaching $166 million, marking the company's first-ever annual sales exceeding $1 billion, indicating strong market demand and growth potential.
- Enhanced Profitability: The company reported adjusted EBITDA of $68 million for Q4, with a gross margin of 25.8% and net income of $39 million, demonstrating significant improvements in cost control and operational efficiency, further solidifying its market position.
- International Market Expansion: In 2025, over half of Balchem's sales growth originated from markets outside the United States, highlighting the success of its globalization strategy, which is expected to provide robust momentum for continued growth in the future.
- Ongoing Investments and Buybacks: The company invested $43 million in capital projects and repurchased approximately 685,000 shares at an average cost of $158 per share, while also increasing its annual dividend to $0.96, marking the 17th consecutive year of dividend growth, reflecting confidence in its financial health and commitment to shareholders.
See More
Balchem (BCPC) Q4 2025 Earnings Call Transcript
See More
Balchem Q4 Earnings Exceed Expectations
- Earnings Beat: Balchem reported a Q4 Non-GAAP EPS of $1.31, exceeding expectations by $0.03, which underscores the company's robust profitability and enhances investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $263.6 million, reflecting a 9.8% year-over-year increase and surpassing expectations by $4.01 million, indicating strong sales performance across all business segments.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $67.9 million, showcasing the company's success in cost management and operational efficiency, thereby strengthening its competitive position in the market.
- Strong Free Cash Flow: With free cash flow of $51.2 million and cash flows from operations at $67.3 million, Balchem demonstrates solid cash generation capabilities, providing strong support for future investments and shareholder returns.
See More
